| Added by | liaudet-coopman |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial |
| Creator | Guiu et al. |
| Author | Séverine Guiu |
| Author | Céline Charon-Barra |
| Author | Pierre Fumoleau |
| Author | Mario Campone |
| Author | Marc Spielmann |
| Author | Henri Roché |
| Author | Christel Mesleard |
| Author | Laurent Arnould |
| Author | Jérôme Lemonnier |
| Author | Magali Lacroix-Triki |
| Abstract | AIM: Microarray studies identified a subgroup of molecular apocrine tumors (estrogen receptor [ER] negative/androgen receptor [AR] positive) that express luminal genes including FOXA1. FOXA1 may direct AR to sites normally occupied by ER in luminal tumors, inducing an estrogen-like gene program that stimulated proliferation. MATERIALS & METHODS: Expression of AR and FOXA1 was evaluated by immunohistochemistry in 592 patients with nonmetastatic triple-negative breast cancer (TNBC). RESULTS: Coexpression of AR and FOXA1 was found in 15.2% of patients. These tumors were more frequently lobular, found in older patients and exhibited a lower nuclear grade and a greater degree of node involvement. They less often exhibited lymphocytic infiltrate, pushing margins, syncytial architecture, central fibrosis or necrosis. CONCLUSION: TNBC with coexpression of AR and FOXA1 seems to behave like luminal tumors with a morphological profile distinct from other TNBC. These biomarkers could be useful to identify a subgroup of TNBC and could have future therapeutic implications. |
| Publication | Future Oncology (London, England) |
| Volume | 11 |
| Issue | 16 |
| Pages | 2283-2297 |
| Date | 2015 |
| Journal Abbr | Future Oncol |
| Language | eng |
| DOI | 10.2217/fon.15.102 |
| ISSN | 1744-8301 |
| Short Title | Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer |
| Library Catalog | PubMed |
| Extra | PMID: 26260807 |
| Tags | Adult, Antineoplastic Combined Chemotherapy Protocols, clinic, Female, FOXA1, Gene Expression, Hepatocyte Nuclear Factor 3-alpha, Humans, Immunohistochemistry, Middle Aged, molecular apocrine tumors, Neoplasm Grading, Neoplasm Staging, Odds Ratio, Receptors, Androgen, Triple Negative Breast Neoplasms, Tumor Burden |
| Date Added | 2018/09/26 - 14:32:38 |
| Date Modified | 2019/05/29 - 12:14:14 |
Institut de Recherche en Cancérologie de
